TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE
Clinical safety rating: safe
CNS depressants may enhance sedative effects May cause marked drowsiness and impair mental and physical abilities.
Codeine is a prodrug converted to morphine, a mu-opioid receptor agonist, producing analgesia and antitussive effects. Triprolidine is a first-generation antihistamine blocking H1 receptors, reducing histamine effects. Pseudoephedrine is a sympathomimetic amine acting as a decongestant via alpha-adrenergic receptor agonism in respiratory tract mucosa.
| Metabolism | Codeine is primarily metabolized by CYP2D6 to morphine (active), CYP3A4 to norcodeine, and to a lesser extent by glucuronidation. Triprolidine is metabolized by hepatic enzymes. Pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted unchanged in urine. |
| Excretion | Codeine: renal elimination of metabolites (primarily codeine-6-glucuronide, norcodeine, and morphine glucuronides); approximately 90% excreted renally, with about 10% as unchanged codeine. Triprolidine: renal elimination (80-90% as metabolites, <5% unchanged). Pseudoephedrine: renal elimination (70-90% unchanged, dependent on urine pH). |
| Half-life | Codeine: 2.5-3.5 hours; clinical context: short half-life necessitates frequent dosing. Triprolidine: 3-5 hours; clinical context: typical dosing every 4-6 hours. Pseudoephedrine: 5-8 hours (alkaline urine prolongs to ~10-13 hours); clinical context: extended-release formulations available. |
| Protein binding | Codeine: ~7-25% bound to albumin. Triprolidine: no specific data, likely low (<20%). Pseudoephedrine: negligible (<5%) binding to plasma proteins. |
| Volume of Distribution | Codeine: 3-6 L/kg. Triprolidine: approximately 2-4 L/kg. Pseudoephedrine: 2-3 L/kg. Clinical meaning: large Vd indicates extensive tissue distribution. |
| Bioavailability | Oral: Codeine ~53% (extensive first-pass metabolism). Triprolidine: not well established; estimated 70-80% (based on related alkylamines). Pseudoephedrine: ~100% (well absorbed, minimal first-pass metabolism). |
| Onset of Action | Oral: Codeine analgesia 30-60 minutes; Triprolidine antihistamine effect 1-2 hours; Pseudoephedrine decongestant effect 15-30 minutes. |
| Duration of Action | Codeine: 4-6 hours (analgesia). Triprolidine: 4-6 hours (antihistamine). Pseudoephedrine: 4-6 hours (immediate-release), up to 12 hours (extended-release). Clinical note: Combined formulation duration is limited by the shortest-acting component. |
Oral: 1 tablet (triprolidine 2.5 mg, pseudoephedrine 60 mg, codeine 30 mg) every 4-6 hours as needed; maximum 4 tablets per day.
| Dosage form | SYRUP |
| Renal impairment | GFR 30-50 mL/min: Administer every 6 hours; GFR 10-29 mL/min: Administer every 8 hours; GFR <10 mL/min: Not recommended due to risk of codeine accumulation. |
| Liver impairment | Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose or extend interval (e.g., every 8 hours); Child-Pugh Class C: Contraindicated. |
| Pediatric use | Not recommended for children under 18 years due to risk of respiratory depression from codeine. For ages ≥18, use adult dosing. |
| Geriatric use | Initiate with half the adult dose (e.g., 1/2 tablet) every 6-8 hours; monitor for CNS depression, constipation, and urinary retention; avoid if possible in frail elderly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
CNS depressants may enhance sedative effects May cause marked drowsiness and impair mental and physical abilities.
| FDA category | Animal |
| Breastfeeding | Codeine: excreted in breast milk; M/P ratio ~2.5; risk of infant CNS depression (especially in CYP2D6 ultrarapid metabolizers); AAP recommends caution. Pseudoephedrine: excreted in breast milk; M/P ratio ~2.6; may reduce milk production. Triprolidine: minimal excretion; limited data. Avoid combination; if used, monitor infant for sedation, irritability, and poor feeding. |
| Teratogenic Risk |
■ FDA Black Box Warning
Codeine is contraindicated for postoperative pain management in children following tonsillectomy and/or adenoidectomy due to risk of respiratory depression and death. Concomitant use of codeine with all CYP3A4 inducers or inhibitors, or with alcohol/central nervous system depressants may increase risk of adverse reactions.
| Common Effects | Sedation |
| Serious Effects |
Hypersensitivity to any component; children <12 years of age; postoperative management in children <18 years after tonsillectomy/adenoidectomy; significant respiratory depression; acute or severe bronchial asthma; gastrointestinal obstruction; concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hypertension; coronary artery disease; narrow-angle glaucoma; urinary retention; breastfeeding.
| Precautions | Serious, life-threatening respiratory depression in children; risk of addiction, abuse, and misuse; ultra-rapid metabolizers of CYP2D6 may convert codeine to morphine more rapidly; risk of medication errors; concomitant use with sedatives, hypnotics, or alcohol increases CNS depression; avoid in patients with severe hypertension or coronary artery disease; use caution in hyperthyroidism, diabetes, prostatic hypertrophy, increased intraocular pressure, or seizure disorders. |
Loading safety data…
| FDA Pregnancy Category C for codeine; no controlled data for triprolidine/pseudoephedrine. First trimester: codeine associated with increased risk of congenital malformations (oral clefts, neural tube defects) in some studies; second/third trimester: prolonged use may cause neonatal respiratory depression, withdrawal syndrome (irritability, hypertonia, tremors) and increased risk of preterm birth. Triprolidine/pseudoephedrine: limited data, but pseudoephedrine implicated in gastroschisis and hemifacial microsomia with first-trimester exposure. |
| Fetal Monitoring | Monitor maternal respiratory rate, sedation level, and blood pressure. Fetal monitoring for growth restriction and preterm labor with prolonged use. Neonatal monitoring for withdrawal symptoms (Finnegan scoring) and respiratory depression if used near term. |
| Fertility Effects | No definitive human data. Codeine may alter hypothalamic-pituitary-gonadal axis, potentially affecting ovulation and libido. Pseudoephedrine can cause vasoconstriction of uterine vessels, theoretically impairing implantation; no established effect on fertility. |